Novozymes Past Earnings Performance

Past criteria checks 5/6

Novozymes has been growing earnings at an average annual rate of 5.9%, while the Chemicals industry saw earnings declining at 2.9% annually. Revenues have been growing at an average rate of 18.7% per year. Novozymes's return on equity is 5.7%, and it has net margins of 14.7%.

Key information

5.89%

Earnings growth rate

-2.93%

EPS growth rate

Chemicals Industry Growth	12.93%
Revenue growth rate	18.69%
Return on equity	5.66%
Net Margin	14.70%
Next Earnings Update	05 Nov 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Novozymes makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NVZM.Y Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 26	4,297	632	969	472
31 Mar 26	4,199	597	944	462
31 Dec 25	4,158	584	912	449
30 Sep 25	4,142	547	872	446
30 Jun 25	4,098	565	839	436
31 Mar 25	4,058	459	810	429
31 Dec 24	3,834	306	766	413
30 Sep 24	3,471	314	669	373
30 Jun 24	3,047	283	575	327
31 Mar 24	2,636	334	494	293
31 Dec 23	2,402	406	446	271
30 Sep 23	2,390	430	441	270
30 Jun 23	2,382	460	446	272
31 Mar 23	2,390	487	441	270
31 Dec 22	2,360	494	430	267
30 Sep 22	2,268	460	443	262
30 Jun 22	2,186	418	418	257
31 Mar 22	2,090	416	403	257
31 Dec 21	2,009	423	380	266
30 Sep 21	1,958	427	335	268
30 Jun 21	1,914	409	322	274
31 Mar 21	1,883	389	310	270
31 Dec 20	1,883	380	309	256
30 Sep 20	1,920	415	309	248
30 Jun 20	1,955	405	326	254
31 Mar 20	1,968	439	335	264
31 Dec 19	1,924	422	329	263
30 Sep 19	1,923	411	334	262
30 Jun 19	1,917	434	321	260
31 Mar 19	1,922	417	315	249
31 Dec 18	1,927	432	313	248
30 Sep 18	1,924	427	311	254
30 Jun 18	1,915	429	310	247
31 Mar 18	1,920	423	320	248
31 Dec 17	1,952	419	332	255
30 Sep 17	1,958	421	334	255
30 Jun 17	1,934	412	332	254
31 Mar 17	1,919	414	328	251
31 Dec 16	1,902	410	325	251
30 Sep 16	1,864	394	327	247
30 Jun 16	1,883	394	333	253
31 Mar 16	1,883	384	331	259
31 Dec 15	1,876	378	330	254
30 Sep 15	1,840	366	320	255

Quality Earnings: NVZM.Y has high quality earnings.

Growing Profit Margin: NVZM.Y's current net profit margins (14.7%) are higher than last year (13.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NVZM.Y's earnings have grown by 5.9% per year over the past 5 years.

Accelerating Growth: NVZM.Y's earnings growth over the past year (11.8%) exceeds its 5-year average (5.9% per year).

Earnings vs Industry: NVZM.Y earnings growth over the past year (11.8%) exceeded the Chemicals industry 2.4%.

Return on Equity

High ROE: NVZM.Y's Return on Equity (5.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/11 11:09
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Cezara Lozneanu	Barclays
Alexander Sloane	Barclays
Sebastian Satz	Barclays

Novozymes Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Novozymes A/S to Report Fiscal Year 2026 Results on Feb 11, 2027

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Recent updates

Novozymes A/S to Report Fiscal Year 2026 Results on Feb 11, 2027

Novonesis A/S Approves Interim Dividend for the First Six Months of 2026, Payable on August 27, 2026

Novozymes A/S (CPSE:NSIS B) announces an Equity Buyback for €1,000 million worth of its shares.

Novonesis Launches Optiva Triticum to Help Pasta Manufacturers Navigate Wheat Volatility Without Compromising Quality

Novozymes A/S (CPSE:NSIS B) signed a letter of intent to acquire remaining 77% stake in Microbiogen Pty Ltd.

Novonesis A/S Approves Dividend on A and B Share

Novozymes A/S, Annual General Meeting, Mar 23, 2026

Novozymes A/S Proposes Dividend for Full Year 2025

Novozymes A/S Revises Earnings Guidance for the Year 2025

Novonesis A/S Approves Interim Dividend for First Half of 2025

Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).

Novonesis A/S Maintains Earnings Guidance for the Year 2025

Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026

Novonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its Committees

Novonesis A/S Announces Board Changes

Novonesis A/S Proposes Dividend, Payable on April 8, 2025

Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025

Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).